To validate this hypothesis, a comparative quantification of Tau pathology across APOE genotypes was performed in the frontal cortex of 21 advanced sporadic AD cases, after an anti-pTau PHF1 immunohistochemistry (n = 11 APOEε3/ε3 and n = 10 APOEε4/ε4 cases). This evidence concerns the gene APOE and Alzheimer disease.